Rare diseases
Investigational molecules
Locations
346 conditions with trials, the busiest first
960 trials across Europe, recruiting first
A study of ACR-368 and gemcitabine for patients with endometrial cancer
FranceStudy of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.
FranceStudy of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer
AustriaA study of progesterone after letrozole treatment for women with infertility undergoing intrauterine insemination
DenmarkA study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer
BelgiumA study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer
FranceStudy of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.
FranceStudy of chlorhexidine, metronidazole, and FB301 for the treatment of women with bacterial vaginosis
GermanyA study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer
AustriaA study to evaluate the effects of lutetium (177lu) vipivotide tetraxetan in patients with metastatic hormone sensitive prostate cancer receiving androgen deprivation therapy.
GermanyA study to evaluate the long-term safety of apremilast in children with oral ulcers from Behçet’s disease or juvenile psoriatic arthritis
GreecePhase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer
BelgiumThe therapies tested most often in Reproductive system and breast disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
